Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease
Status:
Unknown status
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that Nilotinib will be safe in individuals with mild to
moderate AD. Specifically, investigators hypothesize that low daily oral doses of Nilotinib
will lead to CSF penetration, CNS Abl inhibition, and stabilization of CSF total Tau and
p-Tau231/181 and Abeta42/40 levels. The investigators hypothesize that Nilotinib will
decrease brain load of amyloid using amyloid positron emission tomography (PET). The
investigators also predict that Nilotinib will reduce CSF markers of cell death, including
neuron specific enolase (NSE) and S100B.